March 28th 2023
Durvalumab plus tremelimumab and hypofractionated radiotherapy yields observable clinical benefits in patients with gynecologic cancers, according to an expert from The University of Texas MD Anderson Cancer Center.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
The 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies™
Community Practice Connections®: How Are We Personalizing Integration of ICIs and Targeted Therapies to Optimize Outcomes in Endometrial Cancer?
Medical Crossfire®: How Are We Personalizing Integration of ICIs and Targeted Therapies to Optimize Outcomes in Endometrial Cancer?
Medical Crossfire®: How Are We Integrating Immune Checkpoint Inhibitors and Targeted Therapies to Personalize Therapy in Endometrial Cancer?
Addressing Racial and Ethnic Disparities in Breast Cancer Care: Improving Outcomes Across the Spectrum of Diagnosis, Trial Access, and Patient Care
Burst CME™: What You Need to Know About the Evolving Role of TIL Therapy in Cancer Treatment
Comprehensive Geriatric Assessments Key to Treatment Planning in Elderly PatientsOctober 26th 2017
Comprehensive geriatric assessments will play an increasingly important role in identifying patient frailty and personalizing geriatric oncology treatment, according to recently published reviews.
HPV Vaccine Not Linked to Serious Complications in Adult WomenOctober 22nd 2017
A large cohort study found no concerning safety issues associated with the use of human papillomavirus (HPV) vaccine in adult women. There was an increased rate of celiac disease, but this may be related to general underdiagnosis of the condition and its unmasking at vaccination visits.
Extending Platinum-Free Interval in Ovarian Cancer Does Not Improve OutcomesOctober 18th 2017
Extending the platinum-free interval following disease progression in ovarian cancer with a non-platinum agent does not improve outcomes over the standard practice of using a platinum-based chemotherapy, according to a prospective trial.
USPSTF Proposes New Guidelines for Cervical Cancer ScreeningOctober 11th 2017
The USPSTF issued a new draft recommendation for cervical cancer screening, recommending screening with cervical cytology every 3 years for women aged 21 to 29, and offering a choice between cytology every 3 years and high-risk human papillomavirus testing every 5 years for those aged 30 to 65 years.
No Survival Benefit With Adjuvant Chemo for Most Endometrioid, Ovarian Clear Cell CancersOctober 9th 2017
A large database study found that most patients with stage I endometrioid epithelial ovarian cancer or ovarian clear cell cancer do not have better survival outcomes when treated with adjuvant chemotherapy.
Dose-Dense Chemotherapy Fails to Improve PFS in Ovarian CancerSeptember 8th 2017
Weekly dose-dense chemotherapy can be delivered successfully and with lower toxicity than standard 3-weekly regimens, but it does not improve progression-free survival among patients with epithelial ovarian cancer, according to a large new study presented at the ESMO.
Endometrial Cancer Patients Not Offered Genetic Counseling ReferralsJune 19th 2017
According to a study recently presented at the 2017 American Society of Clinical Oncology Annual Meeting, held June 2–6 in Chicago, women diagnosed with endometrial cancer are oftentimes not provided with genetic counseling referrals.
Olaparib Associated With Improved Quality of Life in Ovarian CancerJune 3rd 2017
Despite toxicity, olaparib maintenance therapy is associated with improved patient-reported symptoms outcomes and improved quality-adjusted progression-free survival among patients with germline BRCA mutation-positive, platinum-sensitive relapsed serious ovarian cancer.
Some Older Women Still Need Cervical Cancer ScreeningMay 17th 2017
The number of women who undergo regular screening for cervical cancer drops as they get older, and while this is acceptable if women have been followed regularly until the age of 65 years, women who are not up to date with screening should be screened when they are older.
POINT: Is Lymphadenectomy Required in Endometrial Cancer for Adequate Surgical Staging?May 15th 2017
The diagnostic benefits of SLN evaluation include an ability to identify the extent of tumor dissemination and the utility of SLN mapping in guiding targeted adjuvant treatment in high-risk patients.
COUNTERPOINT: Is Lymphadenectomy Required in Endometrial Cancer for Adequate Surgical Staging?May 15th 2017
The question that should be posed to those who advocate for lymphadenectomy as a tool to guide the adjuvant therapy of endometrial cancer is: At what cost to the patient is lymphadenectomy performed?
Cancer Antigen Expression Associated With Prognosis in Ovarian CancerMay 3rd 2017
Patients with ovarian cancer who express the NY-ESO-1 testis antigen have significantly shorter overall survival than those who do not, according to a new study. These patients may benefit from immunotherapy agents.